Amgen Announces FDA Approval of BioVex Drug Imlygic

Amgen bought BioVex and its Phase III drug Imlygic in March 2011. The upfront payment was $425m with additional payments of up to $575m based on achievement of regulatory and sales milestones.

The US FDA approved Imlygic for sale on 27 October 2015.

In addition, the European regulator (CHMP) recommended on 23 October 2015 that Imlygic be approved by the European Commission.

BioVex Limited

BioVex Limited
Oncology drug development


Latest News

Providence Medical Technology announces new equity financing of $10.5 million

Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.

Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease

Wilson Therapeutics AB has announced that the Phase II study of WTX101 (bis-choline tetrathiomolybdate; Decuperate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint.

MVM invests €15.2m in Valneva SE

Valneva SE is a commercial stage vaccine company with products to prevent Japanese encephalitis and cholera

MVM Life Science Partners LLP closes MVM IV

MVM Life Science Partners LLP announces the closing of a $233 million healthcare fund, MVM IV.

Heptares and Allergan Announce Global R&D and Commercialization Partnership

Heptares and Allergan Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer's and Other Neurological Disorders

bioTheranostics Raises $32 Million in a Private Equity Financing & Announces Spinout From bioMérieux

bioTheranostics, Inc., a leader in molecular diagnostics for cancer, has announced that it has closed a $32 million financing led by MVM Life Science Partners.